Abstract: There is provided a method of therapy of atherosclerosis, by providing microRNA let-7g, an analogue thereof or modified let-7g to organisms to inhibit the expression of lectin-like oxidized low density lipoprotein receptor-1 (LOX-1), and the binding of LOX-1 and oxidized low-density lipoprotein (oxLDL), so as to block the pathogenesis of atherosclerosis. Also, a method of diagnosis of atherosclerosis comprises determining the levels of microRNA let-7g in serum or plasma samples of organisms, in which the levels of microRNA let-7g is estimated in individuals with atherosclerosis as compared to individuals without atherosclerosis.

Abstract: An novel gliclazide nanosphere, the manufacturing method therefor and the application thereof are provided in the present application is provided. The gliclazide nanosphere is prepared by reacting the solid gliclazide with a polymeric matrix for improving the dissolution property and safety of gliclazide, and is benefit for immediately releasing dosage application in clinical therapy.